Ask AI
ProCE Banner Series

Optimizing Management of HER2-Negative MBC: Experts Discuss the Now and Future Roles of TROP-2–Directed ADCs

This 1-hour interactive live roundtable discussion will provide expert perspectives on the current and future roles of TROP-2–directed ADCs in the optimal management of patients with HER2-negative metastatic breast cancer, including the rationale for targeting TROP-2, key data, approvals and guideline recommendations, and approaches to mitigate associated toxicities.

  AMA
  | EBAC®
Who Should Attend

This activity is intended for global oncologists and other healthcare professionals who care for patients worldwide with HER2-negative metastatic breast cancer.

All Events

Optimizing Management of HER2-Negative MBC: Experts Discuss the Now and Future Roles of TROP-2–Directed ADCs

Upcoming Events

October

28

2025

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, confidence, and competence in using TROP-2–directed antibody–drug conjugates for individualized management of patients with HER2-negative metastatic breast cancer.

Target Audience
This activity is intended for global oncologists and other healthcare professionals who care for patients worldwide with HER2-negative metastatic breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan individualized treatment sequences incorporating TROP-2–directed ADCs to optimize clinical outcomes for patients with HER2-negative MBC

  • Implement evidence-based strategies for monitoring, prophylaxis, and management of adverse events associated with ADCs for patients with HER2-negative MBC

  • Evaluate the clinical implications of emerging evidence on novel approaches using ADCs for treatment of HER2-negative MBC, including in earlier lines of therapy and in combination with immunotherapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC® Accreditation

Clinical Care Options, LLC is an EBAC® accredited provider since 2025

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/65f35ab16f6ca.png

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.0 hour of effective education time.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.com to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191